Aardvark Therapeutics, Inc. Common Stock

AARDNASDAQ • USD
ThemeBiotech - Drug Development›Metabolic & Cardiometabolic
1.08 USD
↘ 0.31 (22.30%)AT CLOSE (03:59 PM EDT)
1.05
↘ 0.03 (2.50%)
POST MARKET (AS OF 04:33 PM EDT)
Post Market
AS OF 04:33 PM EDT
1.05
↘ 0.03 (2.50%)
🟢Market: OPEN

Aardvark Therapeutics, Inc. Common Stock (AARD) trades at $1.05 per share. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9 and negative Return on Equity. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Oct 26, 2026.

Open?$1.25
High?$1.39
Low?$0.93
Prev. Close?$1.39
Volume?4.9M
Avg. Volume?708.4K
VWAP?$1.11
Rel. Volume?6.96x
Bid / Ask
Bid?$0.91 × 100
Ask?$1.25 × 100
Spread?$0.34
Midpoint?$1.08
Valuation & Ratios
Market Cap?30.4M
Shares Out?N/A
Float?12.2M
Float %?55.7%
P/E Ratio?N/A
P/B Ratio?0.41
EPS?-$3.19
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Themes
Biotech - Drug Development›Metabolic & CardiometabolicBiotech - Drug Development›Rare Disease Therapeutics
Employees
28
Market Cap
30.4M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.aardvarktherapeutics.com
Listed
2025-02-13
Address
4370 LA JOLLA VILLAGE DRIVE
SAN DIEGO, CA 92122
Phone: (858) 225-7696
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
23
Short Sent.?
44
Piotroski F-Score?0/9Weak
Altman Z-Score?-1.77Distress
Confidence?50%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?3.89%Low
Short Interest?474.1K
Days to Cover?5.3
Free Float12.2M
Avg Daily Volume89.6K
Settlement Date2026-09-30
Financial Health
Current Ratio?12.63Strong
Quick Ratio?12.63Strong
Cash Ratio?11.56Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.41CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
Peers
100
S&P
97
0.6CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-93.4%WEAK▾
ROA?
S&P
3
-85.8%WEAK▾
Cash Flow & Enterprise
FCF?$-69412000
Enterprise Value?$-43429064
Fundamentals ratios updated end of day
MarketsMoversWatchlist